Obermatt
See Similar Stocks →

Kura Oncology

NSQ:KURA · US50127T1097
BiotechnologySmall

360

30
Profit price21
Owner Earnings Yield1
Dividend Yield1
Price/Sales35
Price/Book80
Return on Capital8
Cash Return on Capital12
Return on Equity14
Profit margins9
Accruals84
Owner Earnings Margin21
Sales growth84
Profit growth6
Reinvestment17
Price momentum55
Debt load59
Refinancing14
Debt Payback1
Liquidity1
Analyst ratings72
Opinion Changes50
Price Target Upside98
Market mood83
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kura Oncology doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees267
Websitekuraoncology.com
ISINUS50127T1097
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesHematologyGeneticsOncologyBiopharmaHealth CareMedical

Description

Kura Oncology, Inc. (Kura) operates as a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company has transitioned from a research and development entity to a fully integrated comme…

Analysis

Middle-of-the-road

Kura Oncology, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
25
2026

All-time high

32

Mar 2026

All-time low

25

Jun 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
35
—
—
—
Price/Earnings
59
—
—
—
Price/Book
80
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
56
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kura Oncology with its peers
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rigel Pharmaceuticals
NSQ:RIGL
66
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Rhythm Pharmaceuticals
NMQ:RYTM
31
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →